Torthaí cuardaigh - Ganesh Moorthy

  • 1 - 10 toradh as 10 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, <scp>ACP</scp>‐5862, Using a <scp>Physiologically‐Based Pharmacokinetic</scp> Modeling Approach

    Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, <scp>ACP</scp>‐5862, Using a <scp>Physiologically‐Based Pharmacokinetic</scp> Modeling... de réir Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph A. Ware, J. Greg Slatter, Nidal Al‐Huniti

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Fluconazole Loading Dose Pharmacokinetics and Safety in Infants

    Fluconazole Loading Dose Pharmacokinetics and Safety in Infants de réir Lauren Piper, P. Brian Smith, Christoph P. Hornik, Ira M. Cheifetz, Jeffrey S. Barrett, Ganesh Moorthy, William Hope, Kelly C. Wade, Michael Cohen‐Wolkowiez, Daniel K. Benjamin

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Pharmacokinetics and Safety of Fluconazole in Young Infants Supported With Extracorporeal Membrane Oxygenation

    Pharmacokinetics and Safety of Fluconazole in Young Infants Supported With Extracorporeal Membrane Oxygenation de réir Kevin M. Watt, Daniel K. Benjamin, Ira M. Cheifetz, Ganesh Moorthy, Kelly C. Wade, P. Brian Smith, Kim L. R. Brouwer, Edmund V. Capparelli, Michael Cohen‐Wolkowiez

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Characterization and antifungal activity of the yellow pigment produced by a Bacillus sp. DBS4 isolated from the lichen Dirinaria agealita

    Characterization and antifungal activity of the yellow pigment produced by a Bacillus sp. DBS4 isolated from the lichen Dirinaria agealita de réir Turki M. Dawoud, Naiyf S. Alharbi, Aswani M. Theruvinthalakal, Aswani Thekkangil, Shine Kadaikunnan, Jamal M. Khaled, Taghreed N. Almanaa, Karthikumar Sankar, I. Ganesh Moorthy, Khaled F Alanzi, Shyam Kumar Rajaram

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Characterization and antifungal activity of the yellow pigment produced by a Bacillus sp. DBS4 isolated from the lichen Dirinaria agealita

    Characterization and antifungal activity of the yellow pigment produced by a Bacillus sp. DBS4 isolated from the lichen Dirinaria agealita de réir Dawoud, Turki M., Alharbi, Naiyf S., Theruvinthalakal, Aswani M., Thekkangil, Aswani, Kadaikunnan, Shine, Khaled, Jamal M., Almanaa, Taghreed N., Sankar, Karthikumar, Innasimuthu, Ganesh Moorthy, Alanzi, Khaled F, Rajaram, Shyam Kumar

    Foilsithe / Cruthaithe 2020
    Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán
    Téacs
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations

    Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations de réir Timothy A. Yap, Seock‐Ah Im, Alison M. Schram, Adam Sharp, Judith Balmañà, Richard D. Baird, Jessica Brown, Maria Schwaederlé, Elizabeth A. Pilling, Ganesh Moorthy, Spiros Linardopoulos, Adam Dowson, Carol Pound, Edit Lukacs, Sabina Cosulich, Stephen J. Luen

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

    A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies de réir Trisha M. Wise‐Draper, Ganesh Moorthy, Mohamad A. Salkeni, Nagla Abdel Karim, Hala Elnakat Thomas, Carol A. Mercer, Muhammad S. Beg, Sue O’Gara, Olugbenga Olowokure, Hassana Fathallah, Sara C. Kozma, George Thomas, Olivier Rixe, Pankaj B. Desai, John C. Morris

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

    First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma de réir Erika Hamilton, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer, Janet L. Karlix, Jorge Zerón-Medina, Giulia Fabbri, Paola Marco‐Casanova, Ganesh Moorthy, Maureen M. Hattersley, Gillian M. Littlewood, Patrick D. Mitchell, Jamal Saeh, Gayle P. Pouliot, Kathleen N. Moore

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors de réir Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna V. Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors de réir Atish D. Choudhury, Celestia S. Higano, Johann S. de Bono, Natalie Cook, Dana E. Rathkopf, Kari B. Wisinski, Juan Martín-Liberal, Mark Linch, Elisabeth I. Heath, Richard D. Baird, Javier García-Carbacho, Miguel Quintela‐Fandino, Simon T. Barry, Elza C. de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G. Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I. Shapiro, Lillian L. Siu, Aaron R. Hansen

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: